8-K: Globalink Stockholders Approve Alps Merger

Globalink Investment Inc. stockholders overwhelmingly approved the business combination with Alps Life Sciences Inc. and related charter amendments, paving the way for the merger.

Summary

• Stockholders of Globalink Investment Inc. approved the business combination with Alps Life Sciences Inc. at a special meeting held on October 7, 2025.
• The business combination involves two steps: Globalink merging into Alps Global Holding Pubco (Redomestication Merger) and Alps Biosciences Merger Sub merging into Alps Life Sciences Inc. (Acquisition Merger), making Alps a wholly-owned subsidiary of PubCo.
• All three proposals presented to stockholders, including the Redomestication Merger, Acquisition Merger, and the Net Tangible Asset Charter Amendment, passed with 3,445,007 votes in favor and 0 against for each.
• A key amendment to Globalink's Certificate of Incorporation was approved, eliminating the requirement for net tangible assets of at least $5,000,001 upon consummation of the business combination.
• 59,966 public shares were redeemed for cash in connection with the stockholder votes, leaving only 12,635 public shares outstanding after redemptions.

Sentiment

Score: 7

Explanation: The successful approval of the business combination is a significant positive step, indicating the transaction is moving forward. However, the high redemption rate and the history of multiple deadline extensions introduce some caution regarding investor sentiment and the operational efficiency of the SPAC process.

Positives

• Stockholders overwhelmingly approved the Redomestication Merger, Acquisition Merger, and the Net Tangible Asset Charter Amendment with unanimous votes (3,445,007 For, 0 Against, 0 Abstain for each proposal).
• The successful vote clears a significant hurdle for the completion of the business combination with Alps Life Sciences Inc.
• The elimination of the $5,000,001 net tangible asset limitation provides greater flexibility for the consummation of the business combination.

Negatives

• A significant number of public shares, 59,966, were redeemed for cash, indicating a substantial portion of investors chose not to participate in the combined entity.
• Only 12,635 public shares remain outstanding after redemptions, which represents a very small public float for the combined company.

Risks

• The exceptionally high redemption rate of public shares (approximately 82.6%) significantly reduces the capital available to the combined entity and could lead to low liquidity and high price volatility for the stock post-merger.
• The history of multiple amendments to the Certificate of Incorporation to extend the business combination deadline (First, Second, Third, and Fourth Amendments) suggests potential challenges or delays in the SPAC's ability to finalize the transaction.

Future Outlook

The successful stockholder vote on the business combination proposals and the related charter amendment paves the way for the completion of the merger between Globalink Investment Inc. and Alps Life Sciences Inc., with Alps Global Holding Pubco becoming the surviving publicly traded entity.

Management Comments

• Globalink Investment Inc. has caused this Fifth Amendment to the Amended and Restated Certificate to be duly executed in its name and on its behalf by an authorized officer.

Industry Context

This filing reflects a common trend in the SPAC market where special purpose acquisition companies like Globalink seek to complete business combinations with target companies, in this case, Alps Life Sciences Inc. The exceptionally high redemption rate is also a frequent characteristic of SPAC transactions, often leading to a smaller public float for the combined entity. The repeated extensions to the business combination deadline highlight the complexities and challenges often faced in completing these transactions.

Comparison to Industry Standards

• The redemption rate of approximately 82.6% (59,966 shares redeemed out of an estimated 72,601 initial public shares) is exceptionally high. This rate significantly exceeds typical SPAC redemption averages, which often range from 50-70%, and is comparable to some of the highest redemption rates observed in the SPAC market, such as those seen in the Digital World Acquisition Corp. (DWAC) merger with Trump Media & Technology Group, or other highly speculative or controversial SPAC transactions. Such high redemptions lead to a drastically reduced public float (only 12,635 public shares remaining), potentially impacting liquidity and increasing price volatility for the combined entity, Alps Global Holding Pubco, post-merger.

Corporate Governance

Stakeholder Impact

• Shareholders (Globalink): Those who did not redeem their shares will become shareholders of Alps Global Holding Pubco, participating in the combined entity. Those who redeemed received cash.
• Shareholders (Alps Life Sciences Inc.): Will receive PubCo ordinary shares as merger consideration.
• Management: The current management of Globalink is overseeing the transition to the combined entity.
• Employees: The merger will likely impact employees of both Globalink and Alps, though specific details are not in this filing.

Next Steps

• Completion of the Redomestication Merger, where Globalink merges with and into PubCo.
• Completion of the Acquisition Merger, where Merger Sub merges with and into Alps, making Alps a wholly-owned subsidiary of PubCo.
• PubCo will remain as the surviving publicly traded entity.

Key Dates

Recommendation

The successful stockholder approval of the business combination is a critical positive, removing a significant hurdle for the merger with Alps Life Sciences Inc. However, the exceptionally high redemption rate of approximately 82.6% of public shares is a major concern. This leaves a very small public float of only 12,635 shares, which could lead to low liquidity and high price volatility for the combined entity. While the merger is proceeding, the substantial capital outflow due to redemptions and the history of multiple deadline extensions introduce considerable uncertainty regarding the combined company's immediate financial strength and market performance. A 'hold' recommendation is appropriate to observe the post-merger capital structure, liquidity, and initial operational performance before making a more definitive investment decision.

Keywords

Globalink Investment Inc., Alps Life Sciences Inc., SPAC, Business Combination, Merger, Stockholder Vote, 8-K, SEC Filing, Redomestication, Acquisition, Charter Amendment, Share Redemption, Public Shares